| Cat. No. |
Product Name |
Information |
| PC-23763 |
IEM930
GAS41/YEATS4 inhibitor
|
IEM930 is a small molecule inhibitor targeting the GAS41 YEATS domain (YEATS4)) with ITC binding Kd of 32.6 uM, inhibits GAS41/ITGA4-mediated PI3K/Akt/mTOR signaling pathway in glioma cells. |
| PC-23754 |
CZL-046
p300 bromodomain inhibitor
|
CZL-046 is a potent, selective, and orally active p300 bromodomain inhibitor with IC50 of 3.3 nM, exhibits antiproliferative activity in the multiple myeloma (MM) cell line (OPM-2, IC50=51.5 nM). |
| PC-23522 |
XY221
BRD4 BD2 inhibitor
|
XY221 is a potent, BRD4 BD2-selective inhibitor with IC50 of 5.8 nM, >600-fold selective over BRD4 BD1 and 9–32-fold over BRD2/3/T BD2. |
| PC-23412 |
SR-C-107 (R)
ENL YEATS inhibitor
|
SR-C-107 (R) is a highly potent YEATS domain-containing protein ENL (Eleven-Nineteen-Leukemia) with IC50 of 40 nM, binding KD of 144 nM. |
| PC-22992 |
Y06014
BET inhibitor
|
Y06014 is a selective BRD4(1) inhibitor with IC50 of 4.87 uM. |
| PC-22925 |
GSK2801
BAZ2A/B inhibitor
|
GSK2801 is a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains with KD values of 136 and 257 nM for BAZ2B and BAZ2A, respectively. |
| PC-22528 |
I-BET469
BET inhibitor
|
I-BET469 is a potent, selective pan-BET bromodomain inhibitor with pIC50 of 7.9 for BRD4 BD1, >5000-fold selective over BAZ2A. |
| PC-22527 |
I-BET787
BET inhibitor
|
I-BET787 (GSK3535787) is potent, efficient pan-BET bromodomain inhibitor with pIC50 of 7.1/5.9 for BRD4 BD1/BD2, respectively. |
| PC-22485 |
Y08284
CBP/p300 inhibitor
|
Y08284 is a potent, selective CBP/p300 bromodomain inhibitor with IC50 of 4.21 nM (CBP bromodomain) in HTRF assays. |
| PC-22484 |
Y08207
CBP/p300 inhibitor
|
Y08207 is a potent, selective CBP/p300 bromodomain inhibitor with IC50 of 26.37 nM (CBP bromodomain) in HTRF assays. |
| PC-22483 |
Y08262
CBP/p300 inhibitor
|
Y08207 is a potent, selective CBP/p300 bromodomain inhibitor with IC50 of 73.1 nM (CBP bromodomain) in HTRF assays. |
| PC-22287 |
CDD-1302
BRDT BD2 inhibitor
|
CDD-1302 (CDD1302) is a potent, selective second bromodomain (BD2) of BRDT and BRD4 inhibitor with IC50 of 8 and 12 nM, >1,000-fold and 300-fold selectivity over BRDT-BD1 and BRD4-BD1. |
